Targacept's AZD1446 misses ADHD target

Targacept Inc. (NASDAQ:TRGT) said AZD1446 missed the primary endpoint of significantly improving core symptoms of ADHD after two weeks of treatment vs. placebo in a Phase IIa trial to treat ADHD. The endpoint was measured by CAARS-INV scores. Based on the results, Targacept said that it does not expect partner AstraZeneca plc (LSE:AZN; NYSE:AZN) to continue development of the neuronal nicotinic acetylcholine receptor alpha(4)beta(2) agonist as a treatment for ADHD. The double-blind, crossover, U.S. trial enrolled 79 patients ages 18-65, including 27 nicotine and 52 non-nicotine users. ...